Retatrutide is an investigational peptide agonist targeting the GIP, GLP-1 and glucagon receptors. It has been studied in clinical research involving metabolism and body-weight regulation, but it is not currently an FDA-approved medicine and should not be presented as an approved weight-loss treatment.